Treatment method
AssigneeGenentech, Inc.
InventorsHal Barron, Andrew Chan, Daniel Combs, Wolfgang Dummer, Paul Fielder, Gwendolyn Fyfe
Life of this patent
Estimating the term…
Abstract
The invention provides methods of treating autoimmune diseases using lower doses of anti-CD20 antibodies effective to deplete B cells in the patient.
Claims36
A method of depleting B cells in a patient having an autoimmune disease comprising administering to the patient an antibody that binds human CD20, at a dose in the range of 1 mg to 250 mg.
The method of claim of any of the preceding claims, wherein the autoimmune disease is rheumatoid arthritis.
A method of alleviating an autoimmune disease, comprising administering to a patient having the autoimmune disease, an antibody that binds human CD20 at a dose in the range of 1 mg to 250 mg.
The method of any of the preceding claims, wherein the antibody is a humanized antibody.
The method of any of the preceding claims, wherein the CD20 binding antibody is a chimeric antibody.
The method of any of the preceding claims, wherein the CD20 binding antibody is a human antibody.
The method of any of the preceding claims, wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE) including lupus nephritis, Wegener's disease, inflammatory bowel disease, idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), autoimmune thrombocytopenia, multiple sclerosis, neuromyelitis optica, psoriasis, IgA nephropathy, IgM polyneuropathies, myasthenia gravis, ANCA associated-vasculitis, diabetes mellitus, Reynaud's syndrome, Sjorgen's syndrome and glomerulonephritis.
Dependencies are inferred from the claim text.